IL177511A0 - Process for the synthesis of a cxcr4 antagonist - Google Patents

Process for the synthesis of a cxcr4 antagonist

Info

Publication number
IL177511A0
IL177511A0 IL177511A IL17751106A IL177511A0 IL 177511 A0 IL177511 A0 IL 177511A0 IL 177511 A IL177511 A IL 177511A IL 17751106 A IL17751106 A IL 17751106A IL 177511 A0 IL177511 A0 IL 177511A0
Authority
IL
Israel
Prior art keywords
synthesis
cxcr4 antagonist
cxcr4
antagonist
Prior art date
Application number
IL177511A
Other versions
IL177511A (en
Original Assignee
Anormed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anormed Inc filed Critical Anormed Inc
Publication of IL177511A0 publication Critical patent/IL177511A0/en
Publication of IL177511A publication Critical patent/IL177511A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/40Nitrogen atoms attached in position 8
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL177511A 2004-03-15 2006-08-16 Process for the synthesis of a cxcr4 antagonist IL177511A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55358904P 2004-03-15 2004-03-15
PCT/US2005/008268 WO2005090308A1 (en) 2004-03-15 2005-03-11 Process for the synthesis of a cxcr4 antagonist

Publications (2)

Publication Number Publication Date
IL177511A0 true IL177511A0 (en) 2006-12-10
IL177511A IL177511A (en) 2010-12-30

Family

ID=34993619

Family Applications (1)

Application Number Title Priority Date Filing Date
IL177511A IL177511A (en) 2004-03-15 2006-08-16 Process for the synthesis of a cxcr4 antagonist

Country Status (13)

Country Link
US (1) US7332605B2 (en)
EP (1) EP1730113B1 (en)
JP (1) JP4870660B2 (en)
KR (1) KR20060131899A (en)
CN (1) CN1930127B (en)
AU (1) AU2005224079A1 (en)
BR (1) BRPI0508703B8 (en)
CA (1) CA2558389C (en)
ES (1) ES2614508T3 (en)
IL (1) IL177511A (en)
NO (1) NO20064200L (en)
RU (1) RU2006136381A (en)
WO (1) WO2005090308A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
EP1789045A2 (en) * 2004-08-16 2007-05-30 Smithkline Beecham Corporation Chemical compounds
TW200619206A (en) * 2004-09-29 2006-06-16 Anormed Inc Chemokine-binding heterocyclic compound salts, and methods of use thereof
JP2009524689A (en) * 2006-01-25 2009-07-02 スミスクライン ビーチャム コーポレーション Compound
US20100280010A1 (en) * 2006-01-25 2010-11-04 Kristjan Gudmundsson Chemical compounds
MX2009001272A (en) * 2006-08-02 2009-02-11 Genzyme Corp Combination therapy.
EP2209766A1 (en) * 2007-04-26 2010-07-28 Dr. Reddy's Laboratories (EU) Limited Novel aldehyde composition
FR2934859B1 (en) * 2008-08-05 2010-08-13 Servier Lab NEW PROCESS FOR THE SYNTHESIS OF AGOMELATIN
ME02663B (en) 2010-10-06 2017-06-20 Glaxosmithkline Llc Benzimidazole derivatives as pi3 kinase inhibitors
ES2907489T3 (en) 2015-12-14 2022-04-25 X4 Pharmaceuticals Inc Cancer treatment methods
CN109069486A (en) 2015-12-14 2018-12-21 X4 制药有限公司 The method for the treatment of cancer
DK3393468T3 (en) 2015-12-22 2022-12-19 X4 Pharmaceuticals Inc Methods for treating an immunodeficiency disease
GB201604213D0 (en) * 2016-03-11 2016-04-27 Proximagen Ltd Drug combination and its use in therapy
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
CN109641838A (en) 2016-06-21 2019-04-16 X4 制药有限公司 CXCR4 inhibitor and application thereof
CN116554168A (en) 2016-06-21 2023-08-08 X4 制药有限公司 CXCR4 inhibitors and uses thereof
CA3027495A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
US10548889B1 (en) * 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
WO2022113069A1 (en) 2020-11-24 2022-06-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. E protein channel blockers and orf3 inhibitors as anti-covid-19 agents
JP2023524522A (en) 2020-05-01 2023-06-12 イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー. E protein channel blockers and ORF3 inhibitors as anti-COVID-19 agents
MX2024004165A (en) * 2021-10-07 2024-05-10 X4 Pharmaceuticals Inc Synthesis of mavorixafor and intermediates thereof.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
GB9511357D0 (en) 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
JP4209472B2 (en) * 1997-06-02 2009-01-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ (Imidazole-5-yl) methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation
CN1219780C (en) 1999-03-24 2005-09-21 阿诺麦德股份有限公司 Heterocyclic compounds binding chemotactic factor receptor
TR200300322T2 (en) * 2000-09-15 2003-09-22 Anormed Inc. Heterocyclic compounds that bind the chemokine receptor
NZ524651A (en) * 2000-09-15 2005-08-26 Anormed Inc Chemokine receptor binding heterocyclic compounds for the treatment of HIV or FIV
CZ10903U1 (en) * 2001-01-11 2001-02-19 Oldrich Ing Cihak Bladed water wheel
AU2002357379A1 (en) * 2001-12-21 2003-07-15 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7354932B2 (en) * 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy

Also Published As

Publication number Publication date
KR20060131899A (en) 2006-12-20
US7332605B2 (en) 2008-02-19
BRPI0508703B8 (en) 2021-05-25
BRPI0508703B1 (en) 2020-11-24
CA2558389C (en) 2013-10-08
US20050209277A1 (en) 2005-09-22
RU2006136381A (en) 2008-04-27
CN1930127B (en) 2012-11-21
JP2007529526A (en) 2007-10-25
EP1730113B1 (en) 2016-12-28
EP1730113A1 (en) 2006-12-13
AU2005224079A1 (en) 2005-09-29
EP1730113A4 (en) 2009-12-02
ES2614508T3 (en) 2017-05-31
WO2005090308A1 (en) 2005-09-29
IL177511A (en) 2010-12-30
JP4870660B2 (en) 2012-02-08
NO20064200L (en) 2006-09-15
CN1930127A (en) 2007-03-14
BRPI0508703A (en) 2007-08-07
CA2558389A1 (en) 2005-09-29

Similar Documents

Publication Publication Date Title
IL177511A (en) Process for the synthesis of a cxcr4 antagonist
PL1807395T3 (en) Process for the synthesis of n-alkoxyamines
PT1778618E (en) Synthesis of triethylenetetramines
HK1164320A1 (en) Synthesis of bortezomib
PL1963369T3 (en) Il-21 antagonists
GB0623764D0 (en) Process for the synthesis of hydromorphone
IL183255A0 (en) New process for the preparation of a leukotriene antagonist
EP1940412A4 (en) Novel opioid antagonists
ZA200903889B (en) Process for the synthesis of moxifloxacin hydrochloride
ZA200705130B (en) Process for the synthesis of azetidinones
HK1102568A1 (en) Process for the manufacture of curved objects
IL190686A0 (en) Il-21 receptor antagonists
EP1711484A4 (en) Synthesis of cyanoimino-benzoimidazoles
ZA200704972B (en) Processes for producing 4-aminoquinazolines
EP1794112A4 (en) Synthesis of atomoxetine hydrochloride
ZA200703495B (en) Process for the preparation of irbesartan hydrochloride
IL175695A0 (en) Process for the preparation of valacyclovir hydrochloride
GB0614245D0 (en) Synthesis process
GB2441840B (en) Process for the synthesis of arylfluorenes and analogues thereof
HK1102303A1 (en) Synthesis of ccr5 receptor antagonists ccr5
HU0402017D0 (en) Environment-friend process for the synthesis of quaternary ammonio-steroids
IL178184A0 (en) Synthesis of pyrrole-2-carbonitriles
GB0614246D0 (en) Synthesis process
HK1128287A1 (en) Process for the preparation of tryptase inhibitors
EG24122A (en) Process for the synthesis of 3-cyano-6-alkoxy-7-nitro-4-quinolines

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed